Recent Company News

• 07:01 AM ET Sep 08, 2025
  

  Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

• 09:32 AM ET Jul 31, 2025
  

  Biodexa Pharmaceuticals previously announced ADR ratio change effective ($8.15, -0.49)

• 04:56 PM ET Jul 15, 2025
  

  StreetAccount Summary - After-hours trading

• 04:34 PM ET Jul 15, 2025
  

  Biodexa Pharmaceuticals announces ADR ratio change ($0.88, 0.00)

• 08:35 AM ET Jul 14, 2025
  

  Biodexa Pharmaceuticals announces filing of CTA in Europe for Phase 3 Serenta trial in Familial Adenomatous Polyposis (FAP) ($0.87, 0.00)

• 08:34 AM ET Jun 25, 2025
  

  Biodexa Pharmaceuticals announces activation of first clinical study site for Phase 3 Serenta trial in Familial Adenomatous Polyposis (FAP) ($0.92, 0.00)

• 08:32 AM ET Jun 23, 2025
  

  Biodexa Pharmaceuticals unveils "Serenta" as the name of its upcoming Phase 3 study in Familial Adenomatous Polyposis (FAP) ($0.87, 0.00)

• 07:07 AM ET Jun 18, 2025
  

  Biodexa enrolls first patient in phase 2a study of its type 1 diabetes candidate tolimidone ($0.80, 0.00)

• 08:33 AM ET Jun 04, 2025
  

  Biodexa Pharmaceuticals announces recruitment of first patient in Phase 2 study of tolimidone in Type 1 diabetes ($1.16, 0.00)

• 08:32 AM ET May 30, 2025
  

  Biodexa Pharmaceuticals provides update on cash position and eRapa Phase 3 program ($1.06, 0.00)